Abstract
Seventy-four children with acute lymphoblastic leukaemia had one or more episodes of central nervous system (CNS) leukaemia. 5 children had CNS involvement at diagnosis; 4 survived for less than one year. In 35 children who had not had a previous bone marrow relapse on treatment and who received combination chemotherapy, the median duration of haematological remission from the time of first CNS relapse was almost 3 years. 5 children received full dose (2400 rads) craniospinal irradiation after their first CNS relapse; 4 have remained in CNS and haematological remission for 2 1/2 years or more. 18 children who had a CNS relapse after irradiation received 4-weekly intrathecal methotrexate; in 8 children this was given via an intraventricular reservoir. The median duration of CNS remission in children receiving intrathecal methotrexate was 2 years. Systemic and intrathecal treatment was stopped in 7 children after 2 1/2 years in continuous remission and in 2 children after 2 years. 4 of these 9 children remain in remission at intervals from 41 to 69 weeks off treatment but one is severely retarded. These results show that CNS disease is compatible with prolonged survival, but illustrate the difficulties of eradicating established CNS leukaemia.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aur R. J., Simone J. V., Husto H. O., Verzosa M. S., Pinkel D. Cessation of therapy during complete remission of childhood acute lymphocytic leukemia. N Engl J Med. 1974 Dec 5;291(23):1230–1234. doi: 10.1056/NEJM197412052912306. [DOI] [PubMed] [Google Scholar]
- Duttera M. J., Bleyer W. A., Pomeroy T. C., Leventhal C. M., Leventhal B. G. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet. 1973 Sep 29;2(7831):703–707. doi: 10.1016/s0140-6736(73)92539-7. [DOI] [PubMed] [Google Scholar]
- Hustu H. O., Aur R. J., Verzosa M. S., Simone J. V., Pinkel D. Prevention of central nervous system leukemia by irradiation. Cancer. 1973 Sep;32(3):585–597. doi: 10.1002/1097-0142(197309)32:3<585::aid-cncr2820320311>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
- Kay H. E., Knapton P. J., O'Sullivan J. P., Wells D. G., Harris R. F., Innes E. M., Stuart J., Schwartz F. C., Thompson E. N. Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child. 1972 Jun;47(253):344–354. doi: 10.1136/adc.47.253.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Muriel F. S., Schere D., Barengols A., Eppinger-Helft M., Braier J. L., Pavlovsky S., Macchi G. H., Guman L. Remission maintenance therapy for meningeal leukaemia: intrathecal methotrexate and dexamethasone versus intrathecal craniospinal irradiation with a radiocolloid. Br J Haematol. 1976 Sep;34(1):119–127. doi: 10.1111/j.1365-2141.1976.tb00180.x. [DOI] [PubMed] [Google Scholar]
- Price R. A., Jamieson P. A. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer. 1975 Feb;35(2):306–318. doi: 10.1002/1097-0142(197502)35:2<306::aid-cncr2820350203>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- Shapiro W. R., Young D. F., Mehta B. M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975 Jul 24;293(4):161–166. doi: 10.1056/NEJM197507242930402. [DOI] [PubMed] [Google Scholar]
- Sullivan M. P., Humphrey G. B., Vietti T. J., Haggard M. E., Lee E. Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000-2500 rads tumor dose) in treatment for meningeal leukemia. Cancer. 1975 Apr;35(4):1066–1073. doi: 10.1002/1097-0142(197504)35:4<1066::aid-cncr2820350408>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
- Willoughby M. L. Treatment of overt meningeal leukaemia in children: results of second MRC meningeal leukaemia trial. Br Med J. 1976 Apr 10;1(6014):864–867. doi: 10.1136/bmj.1.6014.864. [DOI] [PMC free article] [PubMed] [Google Scholar]